TNSN97085A1 - OXYBUTERIC SUBSTITUTION OF ACIDS AS METALLOPROTEASE MATRIX INHIBITORS - Google Patents

OXYBUTERIC SUBSTITUTION OF ACIDS AS METALLOPROTEASE MATRIX INHIBITORS

Info

Publication number
TNSN97085A1
TNSN97085A1 TNTNSN97085A TNSN97085A TNSN97085A1 TN SN97085 A1 TNSN97085 A1 TN SN97085A1 TN TNSN97085 A TNTNSN97085 A TN TNSN97085A TN SN97085 A TNSN97085 A TN SN97085A TN SN97085 A1 TNSN97085 A1 TN SN97085A1
Authority
TN
Tunisia
Prior art keywords
oxybuteric
substitution
acids
metalloprotease
metalloprotease matrix
Prior art date
Application number
TNTNSN97085A
Other languages
French (fr)
Inventor
r dixon Brian
Chen Jinshan
Van Zandt Michael
r brittelli David
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of TNSN97085A1 publication Critical patent/TNSN97085A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENTION DONNE DES COMPOSITIONS ET DES METHODES PHARMACEUTIQUES POUR TRAITER CERTAINES CONDITIONS COMPRENANT L'ADMINISTRATION D'UNE QUANTITE DU COMPOSE OU LA COMPOSITION DE L'INVENTION QUI EST EFFECTIVE POUR INHIBITER L'ACTIVITE D'AU MOINS D'UNE MATRICE METALLOPROTEASE POUR ACHEVER LE RESULTAT DU DESIR EFFECTUE : LES COMPOSES DE CETTE INVENTION SONT UNE DE LA FORMULE GENERALISEE : I R = H OU ALKYLE DE 1 – 6 CARBONS LES COMPOSES SONT UTILES POUR L'INHIBITION DE LA MATRICE METALLOPROTEASE ET, DONC COMBATTANT LES CONDITIONS OU MMPs CONTRIBUE. COMME L'OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, ARTHRITIS SEPTIQUE, DE LA RUPTURE DE LA PLAQUE ARTHROSCLEROTIQUE. CETTE PRESENTE INVENTION DONNE AUSSI DES COMPOSITIONS ET DES METHODES PHARMACEUTIQUES POUR TRAITER CES CONDITIONS.THE PRESENT INVENTION PROVIDES PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CERTAIN CONDITIONS INCLUDING THE ADMINISTRATION OF A QUANTITY OF THE COMPOUND OR THE COMPOSITION OF THE INVENTION THAT IS EFFECTIVE FOR INHIBITING THE ACTIVITY OF AT LEAST ONE METALLOPROTEASE MATRIX FOR COMPLETION THE RESULT OF THE DESIRE EFFECTED: THE COMPOUNDS OF THIS INVENTION ARE ONE OF THE GENERALIZED FORMULA: IR = H OR ALKYL OF 1 - 6 CARBONS THE COMPOUNDS ARE USEFUL FOR THE INHIBITION OF THE METALLOPROTEASE MATRIX AND, THUS COMBATTING CONDITIONS OR MMPs CONTRIBUTED. LIKE OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, ARTHRITIS SEPTIC, BREAKING OF THE ARTHROSCLEROTIC PLATE. THIS PRESENT INVENTION ALSO GIVES COMPOSITIONS AND PHARMACEUTICAL METHODS FOR TREATING THESE CONDITIONS.

TNTNSN97085A 1996-05-15 1997-05-09 OXYBUTERIC SUBSTITUTION OF ACIDS AS METALLOPROTEASE MATRIX INHIBITORS TNSN97085A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
TNSN97085A1 true TNSN97085A1 (en) 2005-03-15

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97085A TNSN97085A1 (en) 1996-05-15 1997-05-09 OXYBUTERIC SUBSTITUTION OF ACIDS AS METALLOPROTEASE MATRIX INHIBITORS

Country Status (18)

Country Link
EP (1) EP0912487A1 (en)
JP (1) JP3417951B2 (en)
CN (1) CN1163466C (en)
AR (1) AR007096A1 (en)
AU (1) AU727648B2 (en)
CA (1) CA2253869C (en)
CO (1) CO4990925A1 (en)
HR (1) HRP970246B1 (en)
ID (1) ID20291A (en)
MY (1) MY132470A (en)
PA (1) PA8429401A1 (en)
PE (1) PE65998A1 (en)
SV (1) SV1997000034A (en)
TN (1) TNSN97085A1 (en)
TW (1) TW467892B (en)
WO (1) WO1997043238A1 (en)
YU (1) YU18797A (en)
ZA (1) ZA974032B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EP2184284B1 (en) * 2007-08-15 2013-04-10 Kyorin Pharmaceutical Co., Ltd. Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
CN106458938A (en) 2014-04-03 2017-02-22 拜耳制药股份公司 Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CN106661008A (en) 2014-04-03 2017-05-10 拜耳制药股份公司 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
WO2015150363A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2139183T3 (en) * 1994-01-22 2000-02-01 British Biotech Pharm METALOPROTEINASE INHIBITORS.

Also Published As

Publication number Publication date
AR007096A1 (en) 1999-10-13
CN1225622A (en) 1999-08-11
WO1997043238A1 (en) 1997-11-20
CN1163466C (en) 2004-08-25
JPH11509870A (en) 1999-08-31
CA2253869A1 (en) 1997-11-20
TW467892B (en) 2001-12-11
AU727648B2 (en) 2000-12-21
YU18797A (en) 1999-11-22
PA8429401A1 (en) 2000-05-24
HRP970246B1 (en) 2002-04-30
CA2253869C (en) 2003-04-22
JP3417951B2 (en) 2003-06-16
MY132470A (en) 2007-10-31
SV1997000034A (en) 1999-07-05
PE65998A1 (en) 1998-10-20
HRP970246A2 (en) 1998-04-30
CO4990925A1 (en) 2000-12-26
ID20291A (en) 1998-11-19
ZA974032B (en) 1998-02-19
AU3121997A (en) 1997-12-05
EP0912487A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
MA26697A1 (en) NOVEL GSK-3 INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA200100874A1 (en) POLYMORPHIC CRYSTAL FORMS OF CELLOXYX
ATE208397T1 (en) ARYL SUBSTITUTED 5.5 LINKED AROMATIC NITRO COMPOUNDS AS ANTI-INFLAMMATORY ACTIVES
TNSN97070A1 (en) SUBSTITUTED IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND COMPOSITIONS CONTAINING THEM
AU3249295A (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
WO2002046170A8 (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
CA2260016A1 (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
NL300175I1 (en) Methylsulfonylphenyl 2- (5 H) furanones as inhibitors of COX-2.
BR9709501A (en) Compound, pharmaceutical composition, and processes for treating or preventing schizophrenia and for synthesizing a compound
CA2301742A1 (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
TNSN98127A1 (en) AZETIDINYLPROPYLPIPERIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2190083T3 (en) INHIBITING DIAZEPINOINDOLES OF PHOSPHODIESTERASE 4 '.
TNSN97085A1 (en) OXYBUTERIC SUBSTITUTION OF ACIDS AS METALLOPROTEASE MATRIX INHIBITORS
CA2254731A1 (en) Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
BR9503572A (en) Compound pharmaceutical composition and method of treatment or prevention of a disease
ATE235468T1 (en) PLATELE AGGREGATION INHIBITORS
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
DE69614392D1 (en) Thrombin inhibitor
Miller et al. Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
TNSN97082A1 (en) INHIBITION OF METALLOPROTEASE MATRICES BY SUBSTITUTION OF PHENETYLE COMPOUNDS
NZ287551A (en) N-hydroxyureas that inhibit the 5-lipoxygenase enzyme as anti-inflammatory agents
TNSN97084A1 (en) BIARYL ACETYLENES AS INHIBITORS OF METALLOPROTEINASE MATRICES
TNSN97081A1 (en) INHIBITION OF METALLOPROTEINASE MATRICES BY 2- (W-AROYLKYL) -4-BIARYL-4-OXUBUTYRIC ACIDS